Inhibitor binding to type 4 phosphodiesterase (PDE4) assessed using [3H]piclamilast and [3H]rolipram

Journal of Pharmacology and Experimental Therapeutics

Volumn 305, Issue 2, 2003, Pages 565-572

  Zhao, Yu ^a   Zhang, Han Ting ^a   O'Donnell, James M ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 4,5 DIHYDRO 6 METHYL 5 OXO 4 PROPYL 1,2,4 TRIAZOLO[1,5 A]PYRIMIDINE; 4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; 4 [2 [3 (CYCLOPENTYLOXY) 4 METHOXYPHENYL] 2 PHENYLETHYL]PYRIDINE; CILOMILAST; MAGNESIUM; PHOSPHODIESTERASE IV; PICLAMILAST; ROFLUMILAST; ROLIPRAM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING ASSAY; BINDING SITE; BRAIN REGION; BRAIN TISSUE; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; DRUG BINDING; DRUG INHIBITION; DRUG POTENCY; MALE; MEMBRANE BINDING; NONHUMAN; PRIORITY JOURNAL; RAT;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; BENZAMIDES; BINDING SITES; BRAIN; CEREBRAL CORTEX; CYTOSOL; MAGNESIUM; MALE; MEMBRANES; PHOSPHODIESTERASE INHIBITORS; PYRIDINES; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; ROLIPRAM;

EID: 0037405826     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.047407     Document Type: Article

References (50)

1. Allen RA, Merriman MW, Perry MJ, and Owens RJ (1999) Development of a recombinant cell-based system for the characterisation of phosphodiesterase 4 isoforms and evaluation of inhibitors. Biochem Pharmacol 57:1375-1382.
2. Ashton MJ, Cook DC, Fenton G, Karlsson JA, Palfreyman MN, Raeburn D, Ratcliffe AJ, Souness JE, Thurairatnam S, and Vicker N (1994) Selective type IV phosphodiesterase inhibitors as antiasthmatic agents. The syntheses and biological activities of 3-(cyclopentyloxy)-4-methoxybenzamides and analogues. J Med Chem 37:1696-1703.
3. Bardelle C, Smales C, Ito M, Nomoto K, Wong EY, Kato H, Saeki T, and Staddon JM (1999) Phosphodiesterase 4 conformers: preparation of recombinant enzymes and assay for inhibitors. Anal Biochem 275:148-155.
4. 3H]-rolipram binding. Biochem Pharmacol 51:949-956.
5. Barnette MS, Grous M, Cieslinski LB, Burman M, Christensen SB, and Torphy TJ (1995) Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: correlation between function and interaction with a high-affinity rolipram binding site. J Pharmacol Exp Ther 273:1396-1402.
6. Baures PW, Eggleston DS, Erhard KF, Cieslinski LB, Torphy TJ, and Christensen SB (1993) The crystal structure, absolute configuration and phosphodiesterase inhibitory activity of (+)-1-(4-bromobenzyl)-4-(3-(cyclopentyloxy)-4-methoxyphenyl)- pyrrolidin-2-one. J Med Chem 36:3274-3277.
7. Beavo JA (1995) Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 75:725-748.
8. Beavo JA, Conti M, and Heaslip RJ (1994) Multiple cyclic nucleotide phosphodiesterases. Mol Pharmacol 46:399-405.
9. Bolger GB (1994) Molecular biology of the cyclic AMP-specific cyclic nucleotide phosphodiesterases: a diverse family of regulatory enzymes. Cell Signal 6:851-859.
10. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50% inhibition (150) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
11. Conti M and Jin SL (1999) The molecular biology of cyclic nucleotide phosphodiesterases. Prog Nucleic Acid Res Mol Biol 63:1-38.
12. Davis CW (1984) Assessment of selective inhibition of rat cerebral cortical calcium-independent and calcium-dependent phosphodiesterases in crude extracts using deoxycyclic AMP and potassium ions. Biochim Biophys Acta 797:354-362.
13. Draper NR and Smith H (1966) Applied Regression Analysis, John Wiley & Sons, New York.
14. Duplantier AJ, Biggers MS, Chambers RJ, Cheng JB, Cooper K, Damon DB, Eggler JF, Kraus KG, Marfat A, Masamune H, et al. (1996) Biarylcarboxylic acids and amides: inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret. J Med Chem 39:120-125.
15. Francis SH, Turko IV, and Corbin JD (2001) Cyclic nucleotide phosphodiesterases: relating structure and function. Prog Nucleic Acid Res Mol Biol 65:1-52.
16. Fredholm BB, Brodin K, and Strandberg K (1979) On the mechanism of relaxation of tracheal muscle by theophylline and other cyclic nucleotide phosphodiesterase inhibitors. Acta Pharmacol Toxicol (Copenhagen) 45:336-344.
17. Giembycz MA (1996) Phosphodiesterase 4 and tolerance to beta 2-adrenoceptor agonists in asthma. Trends Pharmacol Sci 17:331-336.
18. Harris AL, Connell MJ, Ferguson EW, Wallace AM, Gordon RJ, Pagani ED, and Silver PJ (1989) Role of low Km cyclic AMP phosphodiesterase inhibition in tracheal relaxation and bronchodilation in the guinea pig. J Pharmacol Exp Ther 251:199-206.
19. Huston E, Pooley L, Julien P, Scotland G, McPhee I, Sullivan M, Bolger G, and Houslay MD (1996) The human cyclic AMP-specific phosphodiesterase PDE-46 (HSPDE4A4B) expressed in transfected COS7 cells occurs as both particulate and cytosolic species that exhibit distinct kinetics of inhibition by, the antidepressant rolipram. J Biol Chem 271:31334-31344.
20. Jacobitz S, McLaughlin MM, Livi GP, Burman M, and Torphy TJ (1996) Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding. Mol Pharmacol 50:891-899.
21. Jacobitz S, Ryan MD, McLaughlin MM, Livi GP, DeWolf WE Jr, and Torphy TJ (1997) Role of conserved histidines in catalytic activity and inhibitor binding of human recombinant phosphodiesterase 4A. Mol Pharmacol 51:999-1006.
22. Karlsson JA, Souness J, Raeburn D, Palfreyman M, and Ashton M (1993) Antiinflammatory effects of novel selective cyclic nucleotide phosphodiesterase inhibitors, in T-Lymphocyte and Inflammatory Cell Research in Asthma (Jolles G, Karlsson J-A, and Taylor J, eds) pp 323-351, Academic Press, London.
23. Kaulen P, Bruning G, Schneider HH, Sarter M, and Baumgarten HG (1989) Autoradiographic mapping of a selective cyclic adenosine monophosphate phosphodiesterase in rat brain with the antidepressant [3H]rolipram. Brain Res 503:229-245.
24. Kelly JJ, Barnes PJ, and Giembycz MA (1996) Phosphodiesterase 4 in macrophages: relationship between cAMP accumulation, suppression of cAMP hydrolysis and inhibition of [3H]R-(-)-rolipram binding by selective inhibitors. Biochem J 318:425-436.
25. Laliberte F, Han Y, Govindarajan A, Giroux A, Liu S, Bobechko B, Lario P, Bartlett A, Gorseth E, Gresser M, et al. (2000) Conformational difference between PDE4 apoenzyme and holoenzyme. Biochemistry 39:6449-6458.
26. Liu S, Laliberte F, Bobechko B, Bartlett A, Lario P, Gorseth E, Van Hamme J, Gresser MJ, and Huang Z (2001) Dissecting the cofactor-dependent and independent bindings of PDE4 inhibitors. Biochemistry 40:10179-10186.
27. Lugnier C, Stierle A, Beretz A, Schoeffter P, Lebec A, Wermuth CG, Cazenave JP, and Stoclet JC (1983) Tissue and substrate specificity of inhibition by alkoxy-aryllactams of platelet and arterial smooth muscle cyclic nucleotide phosphodiesterases relationship to pharmacological activity. Biochem Biophys Res Commun 113:954-959.
28. Makhay MM, Houslay MD, and O'Donnell JM (2001) Discriminative stimulus effects of the type-4 phosphodiesterase inhibitor rolipram in rats. Psychopharmacology 158:297-304.
29. McPhee I, Pooley L, Lobban M, Bolger G, and Houslay MD (1995) Identification, characterization and regional distribution in brain of RPDE-6 (RNPDE4A5), a novel splice variant of the PDE4A cyclic AMP phosphodiesterase family. Biochem J 310:965-974.
30. Manganiello VC, Murata T, Taira M, Belfrage P, and Degerman E (1995) Diversity in cyclic nucleotide phosphodiesterase isoenzyme families. Arch Biochem Biophys 322:1-13.
31. O'Donnell JM (1993) Antidepressant-like effects of rolipram and other inhibitors of cyclic adenosine monophosphate phosphodiesterase on behavior maintained by differential reinforcement of low response rate. J Pharmacol Exp Ther 264:1168-1178.
32. O'Donnell JM and Frith S (1999) Behavioral effects of family-selective inhibitors of cyclic nucleotide phosphodiesterases. Pharmacol Biochem Behav 63:185-192.
33. O'Donnell JM, Wolfe BB, and Frazer A (1984) Agonist interactions with beta adrenergic receptors in rat brain. J Pharmacol Exp Ther 228:640-647.
34. Pooley L, Shakur Y, Rena G, and Houslay MD (1997) Intracellular localization of the PDE4A cAMP-specific phosphodiesterase splice variant RD1 (RNPDE4A1A) in stably transfected human thyroid carcinoma FTC cell lines. Biochem J 321:177-185.
35. Rocque WJ, Tian G, Wiseman JS, Holmes WD, Zajac-Thompson I, Willard DH, Patel IR, Wisely GB, Clay WC, Kadwell SH, et al. (1997) Human recombinant phosphodiesterase 4B2B binds (R)-rolipram at a single site with two affinities. Biochem. istry 36:14250-14261.
36. Ruckstuhl M and Landry Y (1981) Inhibition of lung cyclic AMP- and cyclic GMP-phosphodiesterases by flavonoids and other chromone-like compounds. Biochem Pharmacol 30:697-702.
37. Saldou N, Obernolte R, Huber A, Baecker PA, Wilhelm R, Alvarez R, Li B, Xia L, Callan O, Su C, et al. (1998) Comparison of recombinant human PDE4 isoforms: interaction with substrate and inhibitors. Cell Signal 10:427-440.
38. Schneider HH, Schmiechen R, Brezinski M, and Seidler J (1986) Stereospecific binding of the antidepressant rolipram to brain protein structures. Eur J Pharmacol 127:105-115.
39. Schwabe U, Miyake M, Ohga Y, and Daly JW (1976) 4-(3-Cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone(ZK 62711): a potent inhibitor of adenosine cyclic 3′, 5′-monophosphate phosphodiesterases in homogenates and tissue slices from rat brain. Mol Pharmacol 12:900-910.
40. Soderling SH and Beavo JA (2000) Regulation of cAMP and GMP signaling: new phosphodiesterases and new functions. Curr Opin Cell Biol 12:174-179.
41. Souness JE, Griffin M, Maslen C, Ebsworth K, Scott LC, Pollock K, Palfreyman MN, and Karlsson JA (1996) Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a "low-affinity" phosphodiesterase 4 conformer. Br J Pharmacol 118:649-658.
42. Souness JE, Houghton C, Sardar N, and Withnall MT (1997) Evidence that cyclic AMP phosphodiesterase inhibitors suppress interleukin-2 release from murine splenocytes by interacting with a "low-affinity" phosphodiesterase 4 conformer. Br J Pharmacol 121:743-750.
43. Souness JE, Houghton C, Sardar N, and Withnall MT (1999) Suppression of anti-CD3-induced interleukin-4 and interleukin-5 release from splenocytes of Mesocestoides corti-infected BALB/c mice by phosphodiesterase 4 inhibitors. Biochem Pharmacol 58:991-999.
44. Souness JE, Maslen C, and Scott LC (1992) Effects of solubilization and vanadate/glutathione complex on inhibitor potencies against eosinophil cyclic AMP-specific phosphodiesterase. FEBS Lett 302:181-184.
45. Souness JE, Maslen C, Webber S, Foster M, Raeburn D, Palfreyman MN, Ashton MJ, and Karlsson JA (1995) Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase: comparison with rolipram. Br J Pharmacol 115:39-46.
46. Souness JE and Scott LC (1993) Stereospecificity of rolipram actions on eosinophil cyclic AMP-specific phosphodiesterase. Biochem J 291:389-395.
47. Torphy TJ, Stadel JM, Burman M, Cieslinski LB, McLaughlin MM, White JR, and Livi GP (1992) Coexpression of human cAMP-specific phosphodiesterase activity and high affinity rolipram binding in yeast. J Biol Chem 267:1798-1804.
48. Torphy TJ and Undem BJ (1991) Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. Thorax 46:512-523.
49. Xu RX, Hassell AM, Vanderwall D, Lambert MH, Holmes WD, Luther MA, Roeque WJ, Milburn MV, Zhao Y, Ke H, et al. (2000) Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity. Science (Wash DC) 288:1822-1825.
50. Yarwood SJ, Steele MR, Scotland G, Houslay MD, and Bolger GB (1999) The RACK1 signaling scaffold protein selectively interacts with the cAMP-specific phosphodiesterase PDE4D5 isoform. J Biol Chem 274:14909-14917.